Pharmacokinetics of NNC0519-0130 in Patients with Type 2 Diabetes Mellitus and Varying Renal Function

The primary objective of this study is to evaluate the **pharmacokinetics** of the investigational drug NNC0519-0130 in participants with varying degrees of renal function, including those with normal and reduced kidney function. This is clinically relevant as it aims to understand how **Type 2 Diabetes Mellitus** patients with different renal capabilities metabolize the drug, which can inform dosing adjustments and improve therapeutic outcomes. No secondary objectives are provided in the available data.

The clinical trial involves participants diagnosed with **Type 2 Diabetes Mellitus**. The study population includes both male and female subjects, with an age range spanning from adults to older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been disclosed. The trial population was selected without any specified key inclusion or exclusion criteria being highlighted.

The clinical trial is designed to evaluate the pharmacokinetics of the investigational drug **NNC0519-0130** in participants with varying degrees of renal function, including those with normal and reduced kidney function. The study targets individuals diagnosed with **Type 2 Diabetes Mellitus**. This is a Phase 1 trial, characterized by a **randomized**, **double-blind**, and **controlled** design, ensuring the reliability and validity of the results. The trial is scheduled to commence on April 15, 2024, with an estimated completion date of April 19, 2025, indicating a total duration of approximately one year.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive medical evaluations and laboratory tests to confirm the diagnosis and assess renal function. Following successful screening, participants will be randomized into different study arms. Subsequent visits will be scheduled at regular intervals to monitor drug levels, assess safety, and evaluate any adverse events. These follow-up visits are crucial for collecting data on the drug's pharmacokinetics and ensuring participant safety. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the drug's effects.

The expected length of participant involvement is approximately 12 months, aligning with the overall trial duration. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

No specific details regarding the assessment of efficacy in the clinical trial are provided in the source data. Therefore, information on parameters or endpoints, methods, schedule for measuring, collecting, and analyzing efficacy parameters, as well as tools or instruments involved in efficacy assessments, is not available.